GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Quest Diagnostics Inc (NYSE:DGX) » Definitions » Cash, Cash Equivalents, Marketable Securities

Quest Diagnostics (Quest Diagnostics) Cash, Cash Equivalents, Marketable Securities : $474 Mil (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Quest Diagnostics Cash, Cash Equivalents, Marketable Securities?

Quest Diagnostics's quarterly cash, cash equivalents, marketable securities increased from Sep. 2023 ($143.00 Mil) to Dec. 2023 ($686.00 Mil) but then stayed the same from Dec. 2023 ($686.00 Mil) to Mar. 2024 ($474.00 Mil).

Quest Diagnostics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($872.00 Mil) to Dec. 2022 ($315.00 Mil) but then increased from Dec. 2022 ($315.00 Mil) to Dec. 2023 ($686.00 Mil).


Quest Diagnostics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Quest Diagnostics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest Diagnostics Cash, Cash Equivalents, Marketable Securities Chart

Quest Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,192.00 1,158.00 872.00 315.00 686.00

Quest Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 175.00 126.00 143.00 686.00 474.00

Quest Diagnostics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Quest Diagnostics  (NYSE:DGX) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Quest Diagnostics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Quest Diagnostics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest Diagnostics (Quest Diagnostics) Business Description

Industry
Traded in Other Exchanges
Address
500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Executives
Luis Diaz director C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138
Michael E Prevoznik officer: Corp VP, Legal & Compliance C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Catherine T. Doherty officer: SVP, Physician Services Bus. C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Timothy M Ring director C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Mark E Delaney officer: SVP & Chief Commercial Officer 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Mark A Gardner officer: SVP of Molecular Gen & Oncol 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Patrick Plewman officer: SVP for Diagnostic Services 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Karthik Kuppusamy officer: SVP, Clinical Solutions 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Michael J Deppe officer: VP, Corp. Controller & CAO 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094
Samer Abdul Samad officer: Executive Vice President & CFO 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stephen H Rusckowski director, officer: President and CEO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Tracey Doi director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Gail R Wilensky director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Mark Guinan officer: Senior Vice President & CFO C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel Stanzione director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094

Quest Diagnostics (Quest Diagnostics) Headlines